In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 31, No. 4_suppl ( 2013-02-01), p. 312-312
Abstract:
312 Background: Patients with neuroendocrine carcinoma mostly present with symptomatic metastatic disease due to mass effect or release of biologically active polypeptides or amines and have a 5-year survival rate of 22%. The objective of this study was to assess the efficacy of hepatic artery radioembolization with Yttrium (Y)-90 microspheres in patients with unresectable progressive hepatic metastasis from neuroendocrine tumors. Methods: We conducted a prospective, single institutional, one-arm phase II study at an NCI-designated comprehensive cancer center. The primary endpoint was 6-month progression-free survival (PFS). Secondary endpoints included objective overall response rate (ORR), 1-year overall survival (OS) rate and safety and toxicity profile. Results: A total of 22 patients were enrolled between July 2007 and September 2009 with ECOG performance status 0-1, 45% males and median age of 62.5 (28-88) years. Histology included small bowel carcinoid (n=12), pancreatic neuroendocrine (n=7) and neuroendocrine tumors of unknown primary (n=3). Patients received a median of 2 (1-2) treatments with lobar approach in 95% and segmental approach in 5%. The primary endpoint of 6-month PFS rate in patients with one, two or three hepatic lesions was 82%, 82% and 72% respectively. ORR (partial and complete response) as per RECIST v1.0 was 48% in patients with one lesion, 29% with two lesions and 29% with 3 lesions. Median PFS was 9.4 (8.0-14.8) months. One-year OS rate was 86% and at 2-year was 78%. No procedure related complications were reported and grade 3 toxicities included hyperbilirubinemia (n=1) and elevated alkaline phosphatase (n=1). Conclusions: Y-90 radioembolization is a promising treatment option for patients with unresectable progressive hepatic metastases from neuroendocrine carcinoma with acceptable toxicity. Limited prospective data is available and there is a strong unmet need for randomized clinical trials with radioembolization.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/jco.2013.31.4_suppl.312
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2013
detail.hit.zdb_id:
2005181-5
